Lv69
2820 积分 2023-08-04 加入
LB0005 REPURPSS-II: VALIDATION OF LEFLUNOMIDE-HYDROXYCHLOROQUINE COMBINATION THERAPY IN PATIENTS WITH PRIMARY SJÖGREN'S DISEASE: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED TRIAL
7小时前
求助中
OP0008 SAFETY AND EFFICACY OF ISCALIMAB IN PATIENTS WITH SJÖGREN’S DISEASE: 48-WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
8小时前
已完结
POS0706 LONG-TERM HYDROXYCHLOROQUINE TREATMENT IMPROVES ESSPRI AND ESSDAI IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME
8小时前
已完结
POS0375 ASSESSMENT OF S95011 (OSE-127, LUSVERTIKIMAB), AN ANTI-INTERLEUKIN 7 RECEPTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: AN INTERNATIONAL MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY
8小时前
已完结
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
1天前
已完结
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial
1天前
已完结
Model-Based Meta-Analysis of IL-17 A Inhibitors for Moderate-to-Severe Plaque Psoriasis: Establishing Exposure-Response Relationships to Inform Targeted Drug Development
7天前
已完结
Primary Sjögren’s Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)
17天前
已完结
Interferons in Sjogren’s disease: current status and future prospects
17天前
已完结
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease
17天前
已完结
皖公网安备34019202002308
